Detoxified recombinant botulinum neurotoxin
The present invention relates to the isolation of polypeptides derived from the Clostridium botulinum neurotoxin and the use thereof as immunogens for the production of vaccines and antitoxins, as well as research and drug development applications. Clostridium botulinum is responsible for food bone botulism, a severe and often deadly disease. Botulinum neurotoxin binds to neural cells and are translocated into the cytosol. The toxin then prevents neurotransmitter release by cleaving a SNARE protein. A double mutant E224A/E262 full length botulinum neurotoxin Type A holo form was successfully cloned and purified, which lacks the endopeptidase activity involved in the toxic action of the BoNT, and thus leading to its detoxification (DR BoNT/A). This new molecule can be used as an antidote against botulism, and also as a vaccine candidate for botulism. Due to the poor availability and extreme toxicity of native holo-toxin, a nontoxic form of the holo-toxin is highly desired for research and vaccine development. The full length DR BoNT/A protein has been expressed in E. coli as a soluble form.
1. A composition comprising a non-toxic recombinant type A botulinum protein, wherein said protein comprises a botulinum toxin H (heavy) chain, wherein said protein further comprises a double mutant botulinum toxin L (light) chain, wherein said double mutant comprises E224A/E262A (Glu 224 to Ala 224 /Glu 262 to Ala 262 ), and wherein said protein further comprises at least one non-botulinum toxin chain selected from the group consisting of a C. difficile toxin and a tetanus toxin.
2. The composition of claim 1 , wherein said composition is a vaccine selected from at least one of the group consisting of a botulism vaccine, a tetanus vaccine and a pseudomembranous colitis vaccine.
3. The composition of claim 1 , wherein said composition is a botulism antidote.
4. A drug delivery system comprising a composition comprising a non-toxic recombinant type A botulinum protein attached to a carrier wherein said protein comprises a botulinum toxin H (heavy) chain, wherein said protein further comprises a double mutant botulinum toxin L (light) chain, wherein said double mutant comprises E224A/E262A (Glu 224 to Ala 224 /Glu 262 to Ala 262 ), wherein said protein further comprises at least one non-botulinum toxin selected from the group consisting of a C. difficile toxin and a tetanus toxin.
5. The drug delivery system of claim 4 , wherein said system further comprises a medical device capable of administering the composition to a diseased tissue.
6. The drug delivery system of claim 4 , wherein said carrier comprises a liposome.
7. The drug delivery system of claim 4 , wherein said carrier comprises a microparticle.
8. The drug delivery system of claim 5 , wherein said medical device is selected from the group consisting of a catheter, a sprayer, and a tube.
9. The drug delivery system of claim 5 , wherein said carrier further comprises a drug.
10. The drug delivery system of claim 9 , wherein said drug is effective against botulism or secondary considerations thereof.
11. The drug delivery system of claim 9 , wherein said drug is selected from the group consisting of antiinflammatory, corticosteroid, antithrombotic, antibiotic, antifungal, antiviral, analgesic and anesthetic drugs.